Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations

  • 216 Accesses

  • 30 Citations

Abstract

The pharmacokinetic (PK) behaviour and clinical efficacy of albendazole (ABZ) against hydatid cysts in mice were assessed after treatment with two different ABZ pharmaceutical formulations. BalbC mice received ABZ (0.5 mg/kg) prepared either as solution or suspension (50 μg/ml) for oral administration (PK study). Blood samples were collected up to 16 h post-treatment and processed to measure ABZ/metabolites concentrations in plasma. The clinical efficacy assessment was performed in BalbC mice infected 8 months earlier with Echinococcus granulosus protoscoleces. Infected animals were allocated into three experimental treatment groups: (a) untreated control, (b) ABZ-solution treated, (c) ABZ-suspension treated. Both treated groups received ABZ (0.5 mg/kg) administered under two different therapeutic schemes: dosing every 48 h over 30 days (regimen I) or treated every 12 h during 15 days (regimen II). Experimental mice were sacrificed 12 h after treatment, and cysts were recovered, weighed and processed for transmission electron microscopy. Enhanced ABZ sulphoxide (the main ABZ metabolite) concentration profiles were measured in animals treated with the ABZ solution. Any positive clinical response was obtained after treatment every 48 h (30 days therapy). However, consistent with the observed PK results, both ABZ formulations were clinically effective in infected mice treated with a 12-h dosing interval (15 days therapy).

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2 Fig. 3 Fig. 4 Fig. 5
Fig. 6 Fig. 7 Fig. 8 Fig. 9

References

  1. Ammann R, Eckert J (1995) Clinical diagnosis and treatment of echinococcosis in humans. In: Thompson RCA, Limbery AJ (eds) Echinococcus and hydatid disease. CAB International, Wallingford, UK, pp 441–463

  2. Bartoloni C, Tricerri A, Guidi L, Gambassi G (1992) The efficacy of chemotherapy with mebendazole in human cystic echinococcosis: long-term follow-up of 52 patients. Ann Trop Med Parasitol 86:249–256

  3. Castillo JA, Palomo-Canales J, García JJ, Lastres JL, Torrado JJ (1999) Preparation and characterization of albendazole b-cyclodextrin complexes. Drug Dev Ind Pharm 25:1241–1248

  4. Ceballos L, Alvarez LI, Sanchez Bruni SF, Elissondo C, Dopchiz M, Denegri G, Torrado JJ, Lanusse CE (2006) Development of a cyclodextrin-based flubendazole formulation to control secondary echinococcosis: pharmacokinetics, hydatid cyst morphology and efficacy in mice. J Vet Pharmacol Ther 29:85–86

  5. Davis A, Pawlowski ZS, Dixon H (1986) Multicenter trials of benzimidazole–carbamates in human echinococcosis. Bull World Health Organ 64:383–388

  6. Davis A, Dixon H, Pawlowski ZS (1989) Multicentre clinical trials of benzimidazole carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 67:503–508

  7. Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86:141–159

  8. Eckert J, Deplazes P (2004) Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev 17:107–135

  9. Elissondo C, Dopchiz M, Brasesco M, Denegri G (2004) Echinococcus granulosus: first report of microcysts formation from protoscoleces of cattle origin using the in vitro vesicular culture technique. Parasite 11:415–418

  10. Elissondo C, Ceballos L, Dopchiz M, Andresiuk V, Alvarez LI, Sánchez Bruni SF, Lanusse CE, Denegri G (2007) In vitro and in vivo effects of flubendazole on Echinococcus granulosus metacestodes. Parasitol Res 100:1003–1009

  11. El-On J (2003) Benzimidazole treatment of cystic echinococcosis. Acta Trop 85:243–252

  12. Evrard B, Chiap P, DeTullio P, Ghalmid F, Piela G, Van Heesa T, Crommen J, Losson B, Delattre L (2002) Oral bioavailability in sheep of albendazole from a suspensión and from a solution containing hydroxypropyl-b-cyclodextrin. J Control Release 85:45–50

  13. García JJ, Bolás F, Torrado JJ (2003) Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int J Pharm 250:351–358

  14. Garcıa-Rodriguez J, Torrado JJ, Bolas F (2001) Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole–cyclodextrin complexes. Parasite 8:188–190

  15. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York

  16. Horton RJ (2003) Albendazole for the treatment of echinococcosis. Fundam Clin Pharmacol 17:205–212

  17. Jenkins DJ, Romig T, Thompson RCA (2005) Emergence/re-emergence of Echinococcus spp.—a global update. Int J Parasitol 35:1205–1219

  18. Kohri N, Yamayoshi Y, Xin H, Iseki K, Sato N, Todo S, Miyazaki K (1999) Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 51:159–164

  19. Lanusse CE, Prichard RK (1993) Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Metab Rev 25:235–279

  20. Menezes da Silva A (2003) Hydatid cyst of the liver—criteria for the selection of appropriate treatment. Acta Trop 85:237–242

  21. Moro P, Schantz PM (2006) Cystic echinococcosis in the Americas. Parasitol Int 55:181–186

  22. Pawlowski ZS, Eckert J, Vuitton DA, Ammann RW, Kern P, Craig PS et al (2001) Echinococcosis in humans: clinical aspects, diagnosis and treatment. In: Eckert J, Gemmell MA, Meslin FX, Pawlowski ZS (eds) WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern. World Organisation for Animal Health, Paris, France

  23. Recco P, Hornus E, Frejevus J, Micheau P, Bessieres MH, Roques C, Linas MD (1984) Hydatidose pleurale disseminee et hydatidoses hepatiquesTreatment post-operatoire par flubendazole a propos de 3 cas. Bull Soc Fr Parasitol 3:115–118

  24. Rippman K, Dietrich M, Kern P (1992) Long-term therapy of cystic liver echinococcosis with mebendazole. Medizin Klin 87:350–354

  25. Rodrigues JM, Bories C, Emery I, Fessi H, Devissaguet JP, Liance M (1995) Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. Int J Parasitol 12:1437–1441

  26. Shuhua X, Jiqing Y, Mingjie W, Pieying J, Fanghua G, Junjie C, Wei J, Hotez P (2002) Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis. Acta Trop 82:77–84

  27. Stettler M, Rossignol JF, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thormann W, Dricot E, Segers R, Hemphill A (2004) Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 34:615–624

  28. Teggi A, Lastilla GM, De Rosa F (1993) Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 37:1679–1684

  29. Thompson D, Geary T (1995) The structure and function of helminth surfaces. In: Harr J, Muller M (eds) Biochemistry and molecular biology of parasites. Academic, London, UK

  30. Todorov T, Mechkov G, Georgiev P, Handjiev S, Vutova K, Petkov D et al (1998) Chemotherapy of human cystic hydatid disease: indications, effectiveness, prognosis. Mediterr J Infect Parasitic Diseases 13:89–94

  31. World Health Organization Informal Working Group on Echinococcosis (1996) Guideline for treatment of cysts and alveolar echinococcosis in human. Bull World Health Organ. Informal Working Group on Echinococcosis 74:231–242

  32. World Health Organization Informal Working Group of Echinococcosis (2001) Puncture, aspiration, injection, re-aspiration. An option for the treatment of cystic echinococcosis. World Health Organization, Geneva, Switzerland, pp 1–40

  33. Xiao SH, You JQ, Yang YQ, Guo HF, Zhang CW, Chai JJ, Zhang WL (1988) Histological alterations and drug concentrations in endocysts and cysts fluid of hydatid cysts harboring in mice treated with praziquantel. Acta Pharmacol Sin 9:461–464

Download references

Acknowledgment

This work was partially supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Agencia Nacional de Promoción Científica y Técnica (ANPCyT), both from Argentina.

Author information

Correspondence to Laura Ceballos.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ceballos, L., Elissondo, C., Moreno, L. et al. Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations. Parasitol Res 103, 355–362 (2008). https://doi.org/10.1007/s00436-008-0980-x

Download citation

Keywords

  • Hydatid Cyst
  • Albendazole
  • Untreated Control Group
  • Cystic Echinococcosis
  • Echinococcus Granulosus